DBVT News and Press, DBV Technologies S.A. From 03/15/22

Hycroft Mining (NASDAQ:HYMC) +84% AMC Entertainment is buying 22% of Hycroft Mining Holding. Incannex Healthcare (NASDAQ:IXHL) +66%. Excellon Resources (NYSE:EXN) +23%. Hollysys Automation Technologies (NASDAQ:HOLI) +12%. Anavex Life Sciences (NASDAQ:AVXL) +9% posts mid-st...

Montrouge, France, March 14, 2022 DBV Technologies to Present at the Oppenheimer’s 32nd Annual Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announ...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...

Montrouge, France, March 9, 2022 DBV Technologies Announces Filing of 202 1 Annual Report on Form 10-K and 202 1 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage ...

Gainers: Atreca (NASDAQ:BCEL) +20%. Alignment Healthcare (NASDAQ:ALHC) +16%. Puma Biotechnology (NASDAQ:PBYI) +15%. Humanigen (NASDAQ:HGEN) +13%. agilon health (NYSE:AGL) +8%. Losers: DBV Technologies (NASDAQ:DBVT) -22%. Ocugen (NASDAQ:OCGN) -20%.  ...

Clinical-stage biotech, Humanigen (NASDAQ:HGEN) has added ~6% in the pre-market after two of the senior officers of the company, including Chief Executive Cameron Durrant, disclosed insider purchases through SEC filings on Friday. On Mar. 02, Cameron has bought 40,000 company s...

DBV Technologies (NASDAQ:DBVT) stock declined pre-market following its FY21 results which beat analysts' estimates. Full year 2021 revenue fell -49.38% Y/Y to $5.71M. Net loss decreased to -$97.81M, compared to -$159.56M in 2020. Research and development expenses declined to $70.34M...

DBV Technologies S.A. (DBVT) Q4 2021 Earnings Conference Call March 03, 2022 05:00 PM ET Company Participants Anne Pollak - Head of Investor Relations Daniel Tassé - Chief Executive Officer Sébastien Robitaille - Chief Financial Officer Pharis Mohideen - Chief Medical Officer Confer...

DBV Technologies press release (NASDAQ:DBVT): FY GAAP EPS of -$1.78 beats by $0.28. Revenue of $5.70M (-49.5% Y/Y) beats by $0.83M. For further details see: DBV Technologies GAAP EPS of -$1.78 beats by $0.28, revenue of $5.70M beats by $0.83M

Montrouge, France, March 3, 2022 DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates m VP Pivotal Protocol Complete and Ready for Submission to FDA DBV Continues to E ngage in Productive Exchanges with FDA Cash ...